Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Strother RM, Gopal S, Wirth M, Chadburn A, Noy A, Cesarman E, et al. Challenges of HIV Lymphoma Clinical Trials in Africa: Lessons From the AIDS Malignancy Consortium 068 Study. JCO Glob Oncol. 2020;6:1034-1040.

Verma A, Muthukumar T, Yang H, Lubetzky M, Cassidy MF, Lee JR, et al. Urinary cell transcriptomics and acute rejection in human kidney allografts. JCI Insight. 2020;5(4).

Scholze H, Stephenson RE, Reynolds R, Shah S, Puri R, Butler SD, et al. Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. Blood Adv. 2020;4(20):5226-5231.

Guo R, Zhang Y, Teng M, Jiang C, Schineller M, Zhao B, et al. DNA methylation enzymes and PRC1 restrict B-cell Epstein-Barr virus oncoprotein expression. Nat Microbiol. 2020;5(8):1051-1063.

Batal I, Vasilescu E-, Dadhania DM, Adel AA, S Husain A, Avasare R, et al. Association of HLA Typing and Alloimmunity With Posttransplantation Membranous Nephropathy: A Multicenter Case Series. Am J Kidney Dis. 2020;76(3):374-383.

Rubinstein MM, Goss C, Avecilla ST, Dubé GP, Riely GJ, Mones JV. Management of thymoma-associated pure red cell aplasia: A novel use of blood substitute HBOC-201 in a Jehovah's Witness. Clin Case Rep. 2020;8(2):289-292.

Kim C, Liu SV, Subramaniam DS, Torres T, Loda M, Esposito G, et al. Phase I study of the Lu-DOTA-Tyr-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. J Immunother Cancer. 2020;8(2).

Showalter K, Magro C, Zhang Y, Spiera R, Orange DE, Gordon JK. Response to: 'Correspondence on 'Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement'' by Manetti. Ann Rheum Dis. 2020.

Racine-Brzostek SE, Yang HS, Chadburn A, Orlander D, An A, Campion TR, et al. COVID-19 Viral and Serology Testing in New York City Health Care Workers. Am J Clin Pathol. 2020;154(5):592-595.

Burkhart DL, Morel KL, Wadosky KM, Labbé DP, Galbo PM, Dalimov Z, et al. Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer. Cancer Prev Res (Phila). 2020;13(12):979-988.